9,916 reports of this reaction
3.0% of all CLOPIDOGREL reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for CLOPIDOGREL, manufactured by Sanofi-Aventis U.S. LLC. There are 9,916 FDA adverse event reports linking CLOPIDOGREL to DYSPNOEA. This represents approximately 3.0% of all 332,980 adverse event reports for this drug.
Patients taking CLOPIDOGREL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for CLOPIDOGREL, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for CLOPIDOGREL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 9,916 FDA reports for CLOPIDOGREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.0% of all adverse event reports for CLOPIDOGREL, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking CLOPIDOGREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.